1. Articles in category: Burden of Treatment

    1-24 of 178 1 2 3 4 5 6 7 8 »
    1. Excellent treatment outcomes in children younger than 18 months with stage 4 MYCN nonamplified neuroblastoma.

      Excellent treatment outcomes in children younger than 18 months with stage 4 MYCN nonamplified neuroblastoma.

      Korean J Pediatr. 2018 Feb;61(2):53-58

      Authors: Kim C, Choi YB, Lee JW, Yoo KH, Sung KW, Koo HH

      Abstract Purpose: Although the prognosis is generally good in patients with intermediate-risk neuroblastoma, no consensus has been reached on the ideal treatment regimen.

      Read Full Article
    2. Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model.

      Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model.

      Clin Cancer Res. 2018 Mar 07;:

      Authors: Nguyen F, Alferiev IS, Guan P, Guerrero DT, Kolla V, Moorthy GS, Chorny M, Brodeur GM

      Read Full Article
      Mentions: Nanoparticles
    3. Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells.

      Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells.

      Pharm Res. 2018 Mar 07;35(4):85

      Authors: Gholizadeh S, Dolman EM, Wieriks R, Sparidans RW, Hennink WE, Kok RJ

      Abstract PURPOSE: Sepantronium bromide (YM155) is a hydrophilic quaternary compound that cannot be administered orally due to its low oral bioavailability; it is furthermore rapidly eliminated via the kidneys.

      Read Full Article
    4. Anti-tumor effect of AZD8055 against neuroblastoma cells in vitro and in vivo.

      Anti-tumor effect of AZD8055 against neuroblastoma cells in vitro and in vivo.

      Exp Cell Res. 2018 Feb 27;:

      Authors: Xu DQ, Toyoda H, Yuan XJ, Qi L, Chelakkot VS, Morimoto M, Hanaki R, Kihira K, Hori H, Komada Y, Hirayama M

      Abstract Neuroblastoma (NB) is one of the most common solid tumors in children. High-risk NB remains lethal in about 50% of patients despite comprehensive and intensive treatments.

      Read Full Article
    5. Targeted Doxorubicin-loaded Bacterially Derived Nano-cells for the Treatment of Neuroblastoma.

      Targeted Doxorubicin-loaded Bacterially Derived Nano-cells for the Treatment of Neuroblastoma.

      Mol Cancer Ther. 2018 Feb 28;:

      Authors: Sagnella SM, Trieu J, Brahmbhatt H, MacDiarmid JA, MacMillan A, Whan RM, Fife CM, McCarroll JA, Gifford AJM, Ziegler DS, Kavallaris M

      Read Full Article
      Mentions: Treatment
    6. Updated Data Confirms a Durable 75 Percent Overall Response Rate, by Blinded Independent Review, of Larotrectinib in Adults and Children with Tumors Harboring TRK Fusions

      Updated Data Confirms a Durable 75 Percent Overall Response Rate, by Blinded Independent Review, of Larotrectinib in Adults and Children with Tumors Harboring TRK Fusions

      Larotrectinib, a highly selective TRK kinase inhibitor, shows rapid, potent, and durable efficacy in both adult and pediatric patients with solid tumors that harbor TRK fusions, regardless of tumor type or patient age, according to results from three clinical trials published in the New England Journal of Medicine.

      Read Full Article
    7. Comparison of Cisplatin with Lipoplatin in Terms of Ototoxicity.

      Comparison of Cisplatin with Lipoplatin in Terms of Ototoxicity.

      J Int Adv Otol. 2018 Feb 20;:

      Authors: Serinan E, Altun Z, Aktaş S, Çeçen E, Olgun N

      Abstract OBJECTIVE: Cisplatin (CDDP) is an anti-neoplastic agent that has been used in treatments of both pediatric and adult cancers. It has many side effects, such as ototoxicity, nephrotoxicity, and neurotoxicity. Lipoplatin (LIPO) is a nanomolecule with 110 nm diameter and composed of lipids and CDDP.

      Read Full Article
      Mentions: Side Effects
    8. Vandetanib inhibits cisplatin‑resistant neuroblastoma tumor growth and invasion.

      Vandetanib inhibits cisplatin‑resistant neuroblastoma tumor growth and invasion.

      Oncol Rep. 2018 Feb 09;:

      Authors: Li C, Yang C, Wei G

      Abstract Resistance is the major cause of cisplatin treatment failure in neuroblastoma (NB). Vandetanib is widely used in the treatment of several cancers. In the present study, we aimed to determine the potential of vandetanib in cisplatin‑resistant NB therapy.

      Read Full Article
      Mentions: Treatment
    9. MYCN-amplified neuroblastoma maintains an aggressive and undifferentiated phenotype by deregulation of estrogen and NGF signaling.

      MYCN-amplified neuroblastoma maintains an aggressive and undifferentiated phenotype by deregulation of estrogen and NGF signaling.

      Proc Natl Acad Sci U S A. 2018 Jan 26;:

      Authors: Dzieran J, Rodriguez Garcia A, Westermark UK, Henley AB, Eyre Sánchez E, Träger C, Johansson HJ, Lehtiö J, Arsenian-Henriksson M

      Read Full Article
      Mentions: MYCN
    10. Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma.

      Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma.

      Pediatr Blood Cancer. 2018 Jan 19;:

      Authors: Villablanca JG, Ji L, Shapira-Lewinson A, Marachelian A, Shimada H, Hawkins RA, Pampaloni M, Lai H, Goodarzian F, Sposto R, Park JR, Matthay KK

      Read Full Article
      Mentions: Refractory NANT MYCN
    11. Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma

      The New Approaches to Neuroblastoma Therapy Response Criteria (NANTRC) were developed to optimize response assessment in patients with recurrent/refractory neuroblastoma. Response predictors and associations of the NANTRC version 1.0 (NANTRCv1.0) and prognostic factors with outcome were analyzed.

      Read Full Article
      Mentions: Refractory NANT MYCN
    12. The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma.

      The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma.

      Cancer Immunol Immunother. 2018 Jan 11;:

      Authors: Nguyen R, Houston J, Chan WK, Finkelstein D, Dyer MA

      Read Full Article
      Mentions: Antibody
    13. Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome.

      Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome.

      Oncotarget. 2017 Dec 05;8(63):106820-106832

      Authors: Claeys S, Denecker G, Cannoodt R, Kumps C, Durinck K, Speleman F, De Preter K

      Abstract Background: Neuroblastoma is an aggressive childhood malignancy of the sympathetic nervous system. Despite multi-modal therapy, survival of high-risk patients remains disappointingly low, underscoring the need for novel treatment strategies.

      Read Full Article
      Mentions: Treatment ALK MYCN
    14. Late effects of treatment in survivors of childhood cancers: A single-centre experience.

      Late effects of treatment in survivors of childhood cancers: A single-centre experience.

      Indian J Med Res. 2017 Aug;146(2):216-223

      Authors: Seth R, Singh A, Seth S, Sapra S

      Abstract BACKGROUND & OBJECTIVES: With improved survival of childhood cancer patients, the number of long-term cancer survivors is increasing. Some studies have assessed the long-term morbidity after childhood cancer treatment in the developing countries.

      Read Full Article
    15. Review: The role of radiolabeled DOTA-conjugated peptides for imaging and treatment of childhood neuroblastoma.

      Review: The role of radiolabeled DOTA-conjugated peptides for imaging and treatment of childhood neuroblastoma.

      Curr Radiopharm. 2017 Dec 14;:

      Authors: Alexander N, Vali R, Ahmadzadehfar H, Shammas A, Baruchel S

      Abstract Childhood neuroblastoma is a heterogenous disease with varied clinical presentation and biology requiring different approaches to investigation and management.

      Read Full Article
    16. Incidence and risk factors of bacterial and fungal infection during induction chemotherapy for high-risk neuroblastoma.

      Incidence and risk factors of bacterial and fungal infection during induction chemotherapy for high-risk neuroblastoma.

      Pediatr Hematol Oncol. 2017 Dec 04;:1-12

      Authors: Whittle SB, Williamson KC, Russell HV

      Abstract High-risk neuroblastoma is an aggressive childhood cancer with poor outcomes. Treatment begins with an induction phase comprised of intense multi-agent chemotherapy with the goal of maximally reducing tumor bulk.

      Read Full Article
    17. New developments in immunotherapy for pediatric solid tumors.

      New developments in immunotherapy for pediatric solid tumors.

      Curr Opin Pediatr. 2017 Nov 20;:

      Authors: Schultz LM, Majzner R, Davis KL, Mackall C

      Abstract PURPOSE OF REVIEW: Building upon preclinical advances, we are uncovering immunotherapy strategies that are translating into improved outcomes in tumor subsets. Advanced pediatric solid tumors carry poor prognoses and resultant robust efforts to apply immunotherapy advances to pediatric solid tumors are in progress.

      Read Full Article
      Mentions: Immunotherapy
    18. YmAbs Announces Closing of $30 Million Extension of Private Equity Placement

      NEW YORK--(BUSINESS WIRE)--Y-mAbs Therapeutics, Inc. (YmAbs), an immunotherapy company discovering and developing innovative treatments for patients with cancer, today announced that, further to its press release dated October 24, 2017, the Company has completed an extended closing of an additional $30 million in a private equity placement, adding institutional investors Sofinnova Ventures and Scopia Capital Management to its list of shareholders. Together, with the $50 million raised in the fi

      Read Full Article
      Mentions: Immunotherapy
    19. Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

      Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

      Oncoimmunology. 2017;6(11):e1358331

      Authors: Cheung IY, Kushner BH, Modak S, Basu EM, Roberts SS, Cheung NV

      Read Full Article
      Mentions: Antibody
    20. Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.

      Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.

      Pediatr Hematol Oncol. 2017 Nov 17;:1-12

      Authors: Berthold F, Hömberg M, Proleskovskaya I, Mazanek P, Belogurova M, Ernst A, Sterba J

      Read Full Article
      Mentions: Treatment MYCN
    1-24 of 178 1 2 3 4 5 6 7 8 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles